Now I have enough context from the paper and calibration anchors. Let me compose the final review.

## Summary

MOCHA presents a curated collection of 10 publicly available spatial transcriptomics datasets spanning multiple tissue types, each with pathologist-generated spatial domain annotations. The paper describes the datasets, reviews generic preprocessing and batch correction pipelines, and lists existing multi-sample clustering methods. The stated goal is to provide a resource for developing and evaluating multi-sample SRT methods.

## Strengths

- **Diverse multi-tissue coverage with expert annotations**: The paper compiles 10 SRT cohorts (breast cancer, colorectal cancer, lung cancer, kidney cancer, DLPFC, MOB) spanning multiple tissue types and technology platforms (10x Visium and ST), each with pathologist-generated spatial domain labels. The scale ranges from 3 samples (KC TLS) to 94 samples (BC TNBC), offering variation in sample size and platform that could in principle support multi-sample method evaluation.

## Weaknesses

### Fatal

None.

### Major

- **No experimental validation or demonstration of utility.** The paper contains zero experiments, benchmarks, or analyses that use the MOCHA dataset. There is no evaluation of any multi-sample method on MOCHA, no comparison against existing resources (SORC, Aquila, SODB, STOmicsDB, SpatialDB), no annotation quality assessment, no batch effect characterization, and no use case demonstrating that MOCHA enables anything beyond what the constituent datasets already provided individually. A dataset paper must at minimum show that the resource works for its intended purpose; this paper does not.

- **No demonstrated value over existing resources.** The paper lists several existing repositories but never articulates what MOCHA adds that these resources do not already provide. Many of the cited cohorts (DLPFC, HER2+ breast cancer, TNBC, etc.) are already publicly available with expert annotations from their original publications. The paper presents no evidence that MOCHA's aggregation, re-formatting, or annotation harmonization solves any concrete problem—no incompatible annotation schema is documented, no cross-cohort integration challenge is demonstrated, and no comparison against existing repositories is provided.

- **Incoherence between stated goals and actual content.** The abstract and introduction claim MOCHA provides "standardized data organization, efficient storage formats for large-scale processing, and protocols for handling batch effects." Yet the paper never specifies the storage formats (HDF5? AnnData? A custom schema?), never describes the data organization, and devotes Sections 3 and 4 to generic textbook descriptions of existing methods (Harmony, Crescendo, BayeSMART, BASS, STAGATE) with no MOCHA-specific adaptation. These sections could appear in any SRT tutorial and do not constitute a contribution tied to MOCHA.

### Minor

- **Insufficient detail about the curation process and resource.** Critical information is missing: How many pathologists provided annotations? What were the annotation guidelines? Was inter-rater reliability assessed? How were H&E images co-registered with spatial expression data? The paper mentions grouping annotations into "immune, stroma, tumor, and normal" categories (deferred to Supplementary Material) but does not describe the mapping from the original annotation schemas. No download link, code repository, or data access instructions are provided—the paper states MOCHA "is released" but gives no way to obtain it.

- **Sections 3 and 4 are generic and disconnected from MOCHA.** The preprocessing and batch correction section reads as a general tutorial (library-size normalization, HVGs, SVGs, Harmony, Crescendo) with no indication of which of these steps were actually applied to MOCHA or provided as MOCHA-specific protocols. The multi-sample clustering section is a three-row table of existing methods (BayeSMART, BASS, STAGATE) with no experiments, no analysis, and no connection to the MOCHA resource.

### Trivial

None.

## Nice-to-Haves

- A small-scale demonstration (e.g., running one multi-sample method on 2–3 MOCHA cohorts and reporting standard metrics against the expert annotations) would substantially strengthen the paper and is worth adding before any future submission.

## Removed Points

These points are flagged to be removed, treat them with caution:
- **Strength Finder point about "standardized preprocessing and batch correction protocols"** — The paper describes generic pipelines (Harmony, Crescendo) that are not MOCHA-specific and does not demonstrate that they constitute a standardized framework for the resource. This claimed strength is not supported by the paper content.
- **Harsh Critic criticism about Table 1 being garbled/incomplete** — This is a PDF parsing artifact; the table content is present across the document.
- **Harsh Critic criticism about Figure 1 being "cited but not present"** — PDF parsing artifact; figures present in the original submission.
- **Harsh Critic criticism about missing appendix/supplementary material** — The parser strips these sections; they exist in the original submission.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Run at least one benchmark before submission.** Apply an existing multi-sample method (e.g., BASS or STAGATE) across the MOCHA cohorts and report standard clustering metrics (ARI, NMI) against the expert annotations. This single experiment would transform the paper from an announcement into a validated resource.
2. **Specify the storage format, schema, and access method explicitly** in the main text (not deferred to supplementary material). Provide a download URL or a clear description of how to obtain the data.
3. **Document the annotation curation process**: number of pathologists, annotation guidelines, inter-rater reliability, and the mapping from original annotation schemas to the four broad categories.
4. **Quantify the added value over existing repositories.** Show concretely what MOCHA provides that SORC, Aquila, SODB, STOmicsDB, and SpatialDB do not—for example, consistent annotation schemas across cohorts, standardized file formats, or novel annotations not present in the original publications.

## Score and Decision

### Calibration Anchors

| Anchor Paper | Avg Score | Comparison |
|---|---|---|
| `DdGCjvrFs0.md` — BioSensGraph | 2.50 | Both are resource papers without strong validation; BioSensGraph at least ran link prediction benchmarks—MOCHA has none. |
| `1uujlDeIry.md` — MolPILE | 3.50 | Both present curated resources; MolPILE included retraining experiments showing performance gains—MOCHA has zero experiments. |
| `uVXO6gzVzj.md` — STAMP (Spatial Transcriptomics) | 6.50 | Same domain, but STAMP includes a novel method, extensive benchmarks, and a much larger dataset with demonstrated utility. |
| `SLjqdj3LPk.md` — CHAMMI-75 | 6.00 | Dataset paper with thorough benchmarking, scaling analysis, and demonstrated utility—MOCHA lacks all of these. |
| `SxFOEwQLMT.md` — WetBench | 2.00 | Both are papers where a core claimed contribution is unvalidated; MOCHA's problem is incompleteness rather than fundamental methodological flaw. |
| `ZGzKckA29U.md` — STAGE | 3.00 | Method paper with experiments that other reviewers found insufficient; MOCHA has no experiments at all. |
| `BzNf90Csfa.md` — Curation Leaks | 4.00 | Mixed-reviews paper accepted as poster; included systematic experiments and novel findings—MOCHA has neither. |

**Score positioning**: The most comparable anchor is BioSensGraph (2.50), which was criticized for lacking systematic validation but at least ran benchmark experiments. MOCHA is weaker—it has no experiments, no code/data access, and no demonstrated utility. Even the lowest-scoring dataset papers in the corpus (MolPILE at 3.50, BioSensGraph at 2.50) included experiments that MOCHA entirely lacks. The paper reads as a project announcement, not a completed research contribution. Score: 2.0.

MY FINAL SCORE: <pineapple>2.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>